Business & Industry
- Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)
- Pfizer to acquire Metsera and its next-generation obesity portfolio
- Roche enters into a definitive merger agreement to acquire 89bio
- Novartis to acquire Tourmaline Bio, complementing cardiovascular pipeline with pacibekitug for the treatment of atherosclerotic cardiovascular disease (ASCVD)
- Novartis Leqvio® shows statistically significant and clinically meaningful early LDL-C goal achievement with less muscle pain
Research & Development
- Widely prescribed opioid painkiller tramadol not that effective for easing chronic pain
- Microbiome and nanoparticle discoveries hold promise for treating gut pain
- New antibiotic targets IBD - and AI predicted how it would work before scientists could prove it
- Combination of two drugs that fight cardiovascular risk could also help treat the most common liver disease
- The 2025 Nobel Prize in Physiology or Medicine
- Immune cell ‘signatures’ could help guide treatment for critically ill patients
- Meet your worm avatar: How microscopic worms are helping find new drugs for rare diseases
Conferences & Events
- Cohort data from Denmark show real-world evidence of stable protection against HPV-related cervical cancer
- New insights into T and B cells offer hope for autoimmune disease sufferers
- SAE Media Group proudly presents the 4th Annual AI in Drug Discovery Conference
- SAE Media Group's 6th annual 3D Cell Culture Conference
- CPHI Frankfurt returns to pre-pandemic strength as pharma industry booms again
- 14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies
- CPHI Excellence in Pharma Award Winners 2022
Regulatory Affairs
- FDA approves first gene therapy for treatment of aromatic L-amino acid decarboxylase deficiency
- FDA approves new treatment for hemophilia A or B
- FDA approves nasal spray influenza vaccine for self- or caregiver-administration
- FDA approves first nasal spray for treatment of anaphylaxis
- FDA approves nonsteroidal treatment for Duchenne muscular dystrophy